Helix BioPharma (HBP) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Key Stats

• Today's Range: C$0.96 to C$0.96
• 50-Day Range: C$0.77 to C$0.97
• 52-Week Range: C$0.50 to C$1.35
• Volume: 800 shs
• Average Volume: 2,935 shs
• Market Capitalization: C$50.90 million
• P/E Ratio: N/A
• Dividend Yield: 1.50%
• Price Target: N/A
• Consensus Rating: N/A

HBP Stock Analysis - Frequently Asked Questions

How have HBP shares performed this year?

Helix BioPharma's stock was trading at C$0.89 at the beginning of 2025. Since then, HBP stock has increased by 7.9% and is now trading at C$0.96.
View the best growth stocks for 2025 here.

How were Helix BioPharma's earnings last quarter?

Helix BioPharma Corp. (TSE:HBP) issued its quarterly earnings data on Thursday, October, 24th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter.

How do I buy shares of Helix BioPharma?

Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU).

Company Calendar

• Last Earnings: 10/24/2024
• Today: 5/24/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:HBP
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: +1-416-9253232
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-50,548,392.71
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 1,803.57%
• Return on Assets: -279.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.23
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.08 per share
• Price / Cash Flow: 11.32
• Book Value: C($0.14) per share
• Price / Book: -6.90

Miscellaneous

• Outstanding Shares: 53,021,500
• Free Float: N/A
• Market Cap: C$50.90 million
• Optionable: Not Optionable
• Beta: -0.84